Third-Generation Beta-Blocker — Cardioselective with Nitric Oxide Promotion
Nebivolol is a third-generation, highly cardioselective beta-1 blocker with a unique dual mechanism: it blocks beta-1 adrenergic receptors to reduce heart rate and blood pressure, while also promoting nitric oxide (NO) release for vasodilation. This combination makes it the preferred beta-blocker for performance-oriented clients.
Selectively blocks beta-1 adrenergic receptors in the heart, reducing heart rate, contractility, and cardiac output. Simultaneously stimulates endothelial nitric oxide synthase (eNOS), promoting NO-mediated vasodilation. This dual action lowers blood pressure through both cardiac and vascular pathways.
| Parameter | Details |
|---|---|
| Starting Dose | 2.5 mg/day |
| Standard Dose | 5 mg/day |
| High Dose | 10 mg/day |
| Route | Oral |
| HR Effects | Within hours |
| Full BP Effect | 1–2 weeks |
Never Stop Cold Turkey
MUST taper off Nebivolol — never discontinue abruptly. Sudden cessation causes rebound tachycardia and potentially dangerous blood pressure spikes. Taper over 1–2 weeks under prescriber guidance.
Training Timing
Take Nebivolol AWAY from your workout window. The blunted heart rate response reduces exercise capacity and peak performance. Evening dosing is preferred for clients who train during the day.
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any peptide protocol.